Exact Sciences Corporation (EXAS)
USD 43.97
(0.53%)
USD 43.97
(0.53%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 1.94 Billion USD | -11.57% |
| 2022 | 2.2 Billion USD | 7.69% |
| 2021 | 2.04 Billion USD | 7650.17% |
| 2020 | -27.11 Million USD | -103.53% |
| 2019 | 769.04 Million USD | 45.54% |
| 2018 | 528.39 Million USD | 821.63% |
| 2017 | -73.22 Million USD | -65.33% |
| 2016 | -44.28 Million USD | -22.06% |
| 2015 | -36.28 Million USD | 36.49% |
| 2014 | -57.13 Million USD | -397.18% |
| 2013 | -11.49 Million USD | 1.23% |
| 2012 | -11.63 Million USD | 66.55% |
| 2011 | -34.78 Million USD | 55.27% |
| 2010 | -77.75 Million USD | -271.59% |
| 2009 | -20.92 Million USD | -323.82% |
| 2008 | -4.93 Million USD | -10.05% |
| 2007 | -4.48 Million USD | 7.14% |
| 2006 | -4.83 Million USD | 62.86% |
| 2005 | -13 Million USD | 0.65% |
| 2004 | -13.09 Million USD | 7.8% |
| 2003 | -14.2 Million USD | 18.57% |
| 2002 | -17.43 Million USD | 69.32% |
| 2001 | -56.84 Million USD | -114.75% |
| 2000 | -26.46 Million USD | -644.95% |
| 1999 | -3.55 Million USD | 59.74% |
| 1998 | -8.82 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 2.2 Billion USD | 13.26% |
| 2024 Q3 | 2.16 Billion USD | -3.74% |
| 2024 Q2 | 2.25 Billion USD | 2.08% |
| 2023 Q2 | 1.87 Billion USD | -11.25% |
| 2023 FY | 1.94 Billion USD | -11.57% |
| 2023 Q4 | 1.94 Billion USD | 3.32% |
| 2023 Q3 | 1.88 Billion USD | 0.59% |
| 2023 Q1 | 2.11 Billion USD | -4.12% |
| 2022 Q3 | 2.21 Billion USD | -0.97% |
| 2022 Q1 | 2.19 Billion USD | 7.1% |
| 2022 Q4 | 2.2 Billion USD | -0.3% |
| 2022 FY | 2.2 Billion USD | 7.69% |
| 2022 Q2 | 2.23 Billion USD | 1.85% |
| 2021 Q2 | 2.01 Billion USD | 59.11% |
| 2021 Q4 | 2.04 Billion USD | -2.98% |
| 2021 FY | 2.04 Billion USD | 7650.17% |
| 2021 Q3 | 2.1 Billion USD | 4.58% |
| 2021 Q1 | 1.26 Billion USD | 4777.21% |
| 2020 FY | -27.11 Million USD | -103.53% |
| 2020 Q1 | 964.81 Million USD | 25.46% |
| 2020 Q2 | 980.03 Million USD | 1.58% |
| 2020 Q3 | 907 Million USD | -7.45% |
| 2020 Q4 | -27.11 Million USD | -102.99% |
| 2019 Q3 | -217.3 Million USD | -175.2% |
| 2019 Q2 | 288.96 Million USD | -43.35% |
| 2019 FY | 769.04 Million USD | 45.54% |
| 2019 Q4 | 769.04 Million USD | 453.9% |
| 2019 Q1 | 510.09 Million USD | -3.46% |
| 2018 Q2 | 427.72 Million USD | 24.98% |
| 2018 Q3 | 511.71 Million USD | 19.64% |
| 2018 FY | 528.39 Million USD | 821.63% |
| 2018 Q1 | 342.23 Million USD | 567.39% |
| 2018 Q4 | 528.39 Million USD | 3.26% |
| 2017 Q3 | -46.14 Million USD | 73.73% |
| 2017 Q2 | -175.67 Million USD | -410.13% |
| 2017 Q1 | -34.43 Million USD | 22.24% |
| 2017 FY | -73.22 Million USD | -65.33% |
| 2017 Q4 | -73.22 Million USD | -58.67% |
| 2016 Q3 | -58.6 Million USD | -32.8% |
| 2016 Q1 | -47.23 Million USD | -30.18% |
| 2016 FY | -44.28 Million USD | -22.06% |
| 2016 Q4 | -44.28 Million USD | 24.42% |
| 2016 Q2 | -44.12 Million USD | 6.57% |
| 2015 Q3 | -27.98 Million USD | 7.56% |
| 2015 FY | -36.28 Million USD | 36.49% |
| 2015 Q4 | -36.28 Million USD | -29.64% |
| 2015 Q2 | -30.27 Million USD | 23.17% |
| 2015 Q1 | -39.41 Million USD | 31.02% |
| 2014 Q1 | -16.53 Million USD | -43.91% |
| 2014 FY | -57.13 Million USD | -397.18% |
| 2014 Q4 | -57.13 Million USD | -112.94% |
| 2014 Q3 | -26.82 Million USD | -37.37% |
| 2014 Q2 | -19.53 Million USD | -18.1% |
| 2013 Q1 | -6.42 Million USD | 44.75% |
| 2013 Q3 | -8.26 Million USD | 58.65% |
| 2013 Q4 | -11.49 Million USD | -39.1% |
| 2013 FY | -11.49 Million USD | 1.23% |
| 2013 Q2 | -19.98 Million USD | -210.83% |
| 2012 Q4 | -11.63 Million USD | -7.09% |
| 2012 FY | -11.63 Million USD | 66.55% |
| 2012 Q1 | -11.29 Million USD | 67.53% |
| 2012 Q2 | -5.02 Million USD | 55.49% |
| 2012 Q3 | -10.86 Million USD | -116.16% |
| 2011 Q2 | -37.26 Million USD | 47.57% |
| 2011 Q3 | -3.99 Million USD | 89.28% |
| 2011 Q4 | -34.78 Million USD | -770.61% |
| 2011 FY | -34.78 Million USD | 55.27% |
| 2011 Q1 | -71.07 Million USD | 8.59% |
| 2010 Q2 | -23.23 Million USD | -35.3% |
| 2010 Q4 | -77.75 Million USD | -292.39% |
| 2010 Q1 | -17.17 Million USD | 17.94% |
| 2010 FY | -77.75 Million USD | -271.59% |
| 2010 Q3 | -19.81 Million USD | 14.71% |
| 2009 Q1 | -3.59 Million USD | 27.18% |
| 2009 Q2 | -12.28 Million USD | -241.81% |
| 2009 Q3 | -22.77 Million USD | -85.38% |
| 2009 Q4 | -20.92 Million USD | 8.14% |
| 2009 FY | -20.92 Million USD | -323.82% |
| 2008 Q4 | -4.93 Million USD | 18.65% |
| 2008 Q3 | -6.06 Million USD | -10.27% |
| 2008 Q2 | -5.5 Million USD | -37.63% |
| 2008 Q1 | -3.99 Million USD | 10.86% |
| 2008 FY | -4.93 Million USD | -10.05% |
| 2007 Q2 | -3.83 Million USD | 0.42% |
| 2007 Q4 | -4.48 Million USD | 37.38% |
| 2007 Q3 | -7.16 Million USD | -86.81% |
| 2007 Q1 | -3.85 Million USD | 20.29% |
| 2007 FY | -4.48 Million USD | 7.14% |
| 2006 Q2 | -13.83 Million USD | -33.12% |
| 2006 Q3 | -7.99 Million USD | 42.23% |
| 2006 Q4 | -4.83 Million USD | 39.54% |
| 2006 FY | -4.83 Million USD | 62.86% |
| 2006 Q1 | -10.39 Million USD | 20.11% |
| 2005 FY | -13 Million USD | 0.65% |
| 2005 Q2 | -17.62 Million USD | -88.85% |
| 2005 Q1 | -9.33 Million USD | 28.71% |
| 2005 Q3 | -17.12 Million USD | 2.84% |
| 2005 Q4 | -13 Million USD | 24.04% |
| 2004 Q2 | -13.84 Million USD | 42.74% |
| 2004 Q4 | -13.09 Million USD | 20.91% |
| 2004 Q1 | -24.17 Million USD | -70.27% |
| 2004 FY | -13.09 Million USD | 7.8% |
| 2004 Q3 | -16.55 Million USD | -19.56% |
| 2003 Q4 | -14.2 Million USD | 11.83% |
| 2003 Q1 | -11.78 Million USD | 32.43% |
| 2003 FY | -14.2 Million USD | 18.57% |
| 2003 Q2 | -14.73 Million USD | -25.06% |
| 2003 Q3 | -16.1 Million USD | -9.29% |
| 2002 FY | -17.43 Million USD | 69.32% |
| 2002 Q4 | -17.43 Million USD | 28.57% |
| 2002 Q3 | -24.41 Million USD | 57.87% |
| 2002 Q2 | -57.95 Million USD | -15.47% |
| 2002 Q1 | -50.19 Million USD | 11.69% |
| 2001 Q2 | -67.23 Million USD | 6.55% |
| 2001 Q3 | -62.63 Million USD | 6.84% |
| 2001 Q4 | -56.84 Million USD | 9.25% |
| 2001 Q1 | -71.94 Million USD | 0.0% |
| 2001 FY | -56.84 Million USD | -114.75% |
| 2000 FY | -26.46 Million USD | -644.95% |
| 1999 FY | -3.55 Million USD | 59.74% |
| 1998 FY | -8.82 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | -39.45 Million USD | 5041.06% |
| Applied DNA Sciences, Inc. | -5.91 Million USD | 33061.343% |
| Aspira Women's Health Inc. | -331 Thousand USD | 589026.586% |
| Biodesix, Inc. | 34.3 Million USD | -5582.068% |
| BioNexus Gene Lab Corp. | -5.79 Million USD | 33732.968% |
| bioAffinity Technologies, Inc. | -1.24 Million USD | 156934.692% |
| bioAffinity Technologies, Inc. | -1.24 Million USD | 156934.692% |
| Bionano Genomics, Inc. | 34.88 Million USD | -5488.404% |
| CareDx, Inc | -47.97 Million USD | 4163.171% |
| Check-Cap Ltd. | -24.75 Million USD | 7974.241% |
| Castle Biosciences, Inc. | -83.53 Million USD | 2433.681% |
| DarioHealth Corp. | -7.54 Million USD | 25926.007% |
| Fulgent Genetics, Inc. | -82.56 Million USD | 2460.956% |
| Guardant Health, Inc. | 220.22 Million USD | -785.154% |
| ICON Public Limited Company | 3.56 Billion USD | 45.246% |
| IDEXX Laboratories, Inc. | 493.94 Million USD | -294.646% |
| Illumina, Inc. | 1.21 Billion USD | -60.572% |
| Intelligent Bio Solutions Inc. | -5.43 Million USD | 35982.012% |
| iSpecimen Inc. | -2.14 Million USD | 90876.149% |
| Standard BioTools Inc. | 46.5 Million USD | -4091.603% |
| MDxHealth SA | 18.88 Million USD | -10222.198% |
| 23andMe Holding Co. | -141.37 Million USD | 1478.878% |
| Medpace Holdings, Inc. | -103.32 Million USD | 1986.58% |
| Myriad Genetics, Inc. | 88.1 Million USD | -2112.653% |
| Mainz Biomed B.V. | 349.85 Thousand USD | -557087.12% |
| ENDRA Life Sciences Inc. | -2.43 Million USD | 80007.514% |
| NeoGenomics, Inc. | 269.19 Million USD | -624.15% |
| Neogen Corporation | 735.62 Million USD | -164.991% |
| Inotiv, Inc. | 382.14 Million USD | -410.101% |
| Natera, Inc. | -200.1 Million USD | 1074.177% |
| OpGen, Inc. | 11.89 Million USD | -16292.248% |
| OPKO Health, Inc. | 230.68 Million USD | -745.033% |
| Psychemedics Corporation | 334 Thousand USD | -583536.826% |
| Prenetics Global Limited | -43.33 Million USD | 4598.106% |
| Prenetics Global Limited | -43.33 Million USD | 4598.106% |
| Precipio, Inc. | -386 Thousand USD | 505112.176% |
| Personalis, Inc. | -8.02 Million USD | 24400.012% |
| RadNet, Inc. | 1.14 Billion USD | -69.722% |
| Sera Prognostics, Inc. | -2.02 Million USD | 96506.874% |
| Sotera Health Company | 2.02 Billion USD | 3.755% |
| Neuronetics, Inc. | 2.79 Million USD | -69594.208% |
| Star Equity Holdings, Inc. | -15.33 Million USD | 12810.093% |
| Star Equity Holdings, Inc. | -15.33 Million USD | 12810.093% |
| Trinity Biotech plc | 63.73 Million USD | -2958.471% |
| T2 Biosystems, Inc. | 33.8 Million USD | -5665.764% |
| Twist Bioscience Corporation | -192.4 Million USD | 1113.169% |
| Exagen Inc. | -12.77 Million USD | 15362.661% |